Picture loading failed.

Anti-IL1RL1 therapeutic antibody (Pre-made Astegolimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

The IL-33/ST2 pathway is linked with asthma susceptibility. Inhaled allergens, pollutants, and respiratory viruses, which trigger asthma exacerbations, induce release of IL-33, an epithelial-derived ��alarmin.�� Astegolimab, a human IgG2 mAb, selectively inhibits the IL-33 receptor, ST2.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-033-1mg 1mg 3090
GMP-Bios-ab-033-10mg 10mg 21890
GMP-Bios-ab-033-100mg 100mg 148000
GMP-Bios-ab-033-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-IL1RL1 therapeutic antibody (Pre-made Astegolimab biosimilar,Whole mAb)
INN Name Astegolimab
TargetIL1RL1
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesAmgen;Genentech;University of Leicester
Conditions Approvedna
Conditions ActiveAllergic asthma;Atopic dermatitis;Chronic obstructive pulmonary disease
Conditions DiscontinuedAsthma;Rhinosinusitis
Development Techna